Abstract
The diagnosis of familial non-syndromic clear cell renal cell carcinoma is one of exclusion. In families presenting with clear cell RCC a germline VHL mutation and a consitutional translocation of chromosome 3 must be excluded before familial non-syndromic clear cell RCC can be diagnosed. Large familial non-syndromic clear cell RCC kindreds are uncommon and a predisposing gene has not been identified. However inheritance is autosomal dominant in most cases and age at onset is earlier than in sporadic cases. Recognition and appropriate screening of familial non-syndromic clear cell RCC cases will reduce morbidity and mortality. Large scale collaborative linkage studies may provide a basis for the identification of familial non-syndromic clear cell RCC susceptibility gene(s).
Keywords: renal cell carcinoma, von hippel-lindau(vhl) disease, chromosome, vhl gene mutation, molecular genetic
Current Molecular Medicine
Title: Familial Non-Syndromic Clear Cell Renal Cell Carcinoma
Volume: 4 Issue: 8
Author(s): Emma R. Woodward
Affiliation:
Keywords: renal cell carcinoma, von hippel-lindau(vhl) disease, chromosome, vhl gene mutation, molecular genetic
Abstract: The diagnosis of familial non-syndromic clear cell renal cell carcinoma is one of exclusion. In families presenting with clear cell RCC a germline VHL mutation and a consitutional translocation of chromosome 3 must be excluded before familial non-syndromic clear cell RCC can be diagnosed. Large familial non-syndromic clear cell RCC kindreds are uncommon and a predisposing gene has not been identified. However inheritance is autosomal dominant in most cases and age at onset is earlier than in sporadic cases. Recognition and appropriate screening of familial non-syndromic clear cell RCC cases will reduce morbidity and mortality. Large scale collaborative linkage studies may provide a basis for the identification of familial non-syndromic clear cell RCC susceptibility gene(s).
Export Options
About this article
Cite this article as:
Woodward R. Emma, Familial Non-Syndromic Clear Cell Renal Cell Carcinoma, Current Molecular Medicine 2004; 4 (8) . https://dx.doi.org/10.2174/1566524043359728
DOI https://dx.doi.org/10.2174/1566524043359728 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthetic 2-Methoxyestradiol Derivatives: Structure-Activity Relationships
Current Medicinal Chemistry Artemisia Species as a New Candidate for Diabetes Therapy: A Comprehensive Review
Current Molecular Medicine Glycation and Hypoxia: Two Key Factors for Adipose Tissue Dysfunction
Current Medicinal Chemistry Design, Synthesis and Antitumor Activities of Bis-arylureas and Bis-arylamides Based on1H-benzo[d]imidazole Moiety as Novel BRaf<sup>V600E</sup>/VEGFR2 Dual inhibitors
Letters in Drug Design & Discovery Small Molecule Inhibitors of NF-κB and JAK/STAT Signal Transduction Pathways as Promising Anti-Inflammatory Therapeutics
Mini-Reviews in Medicinal Chemistry TRPM8, a Sensor for Mild Cooling in Mammalian Sensory Nerve Endings
Current Pharmaceutical Biotechnology Introduction: P2 Receptors
Current Topics in Medicinal Chemistry Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer
Current Medicinal Chemistry Potential Deployment of Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type 1 and Type 2 Receptor Blockers in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry ABC Transporters and Drug Resistance in Patients with Epilepsy
Current Pharmaceutical Design Preface: In 2013 Gene Therapy is a Nike; for 2014, Just Do It!
Current Gene Therapy Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Evaluation of Polygonum bistorta for Anticancer Potential Using Selected Cancer Cell Lines
Medicinal Chemistry HDAC as a Therapeutic Target for Treatment of Endometrial Cancers
Current Pharmaceutical Design Pulmonary Hypertension and Systemic Diseases
Current Drug Targets - Inflammation & Allergy SAR, QSAR and Docking of Anticancer Flavonoids and Variants: A Review
Current Topics in Medicinal Chemistry Tyrosine Kinases as Targets for Anti-Inflammatory Therapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Increasing Sensitivity to Radiotherapy and Chemotherapy by Using Novel Biological Agents that Alter the Tumor Microenvironment
Current Molecular Medicine Integrin αvβ3 Antagonists for Anti-Angiogenic Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers
Current Topics in Medicinal Chemistry